Trametinib is a cancer drug. It is a MEK inhibitor drug with anti-cancer activity. It inhibits MEK1 and MEK2. Trametinib had good results for metastatic melanoma carrying the BRAF V600E mutation in a phase III clinical trial.

Trametinib-Associated Bradycardia

Alhazmi, Luai MD1; Karim, Mohammad M. MD2; Al-Sarie, Mohammad MD3; Skeel, Roland MD4; Karim, Saima DO1

American Journal of Therapeutics: June 20, 2019 - Volume Publish Ahead of Print - Issue - p

doi: 10.1097/MJT.0000000000000862

Letters to the Editor: PDF Only

BUY

PAP

• Author Information
• Article Metrics

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.